15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Processa Pharmaceuticals Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $1.00 to $1.00, so the covering firms are broadly aligned. The average target of $1.00 sits 54% below the current $2.18. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.50 next quarter toward $-3.75 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Processa Pharmaceuticals Inc.
As of Aug, 1 of 1 firms rate PCSA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PCSA EPS & revenue forecast
EPS · THIS QUARTER
$-1.50
Range $-1.50 – $-1.50 · 1 analysts · -92% YoY
Next period, 1 analysts expect Processa Pharmaceuticals Inc to earn $-1.50 a share (range $-1.50 – $-1.50), versus $-18.50 a year earlier. , growing to $-3.75 the year after.
REVENUE · THIS QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —)., rising to $0 next year.
Top analysts covering Processa Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PCSA.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #294
Buy
$1.00-54.1% to target
Overall win rate
37%
+ Follow
#2
NR
Naz Rahman
Maxim Group
Hold
No targeton PCSA
Coverage
—
+ Follow
#3
RS
Ram Selvaraju
H.C. Wainwright
Buy
$25.00+1046.8% to target
Coverage
—
+ Follow
PCSA stock forecast FAQ
What is PCSA's average 12-month price target?+
The 1 analysts with a live target average $1.00 for Processa Pharmaceuticals Inc over the next 12 months, ranging from a $1.00 high to a $1.00 low.
Is PCSA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover PCSA?+
1 analysts have an active rating on Processa Pharmaceuticals Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering PCSA?+
Among analysts who currently cover PCSA, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #294). Their current call is Buy with a $1.00 target.
What is Processa Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-1.50 per share (range $-1.50 – $-1.50) across 1 analysts, rising to $-3.75 the following year.
How much revenue is Processa Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is — (range — – —), growing to $0 next year.
Have analysts been upgrading or downgrading PCSA lately?+
As of Aug, 1 of 1 firms rate PCSA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PCSA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
